Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Molecular Characterization and Antibiogram of Acinetobacter Baumannii Clinical Isolates Recovered From the Patients With Ventilator-Associated Pneumonia

Saleem Mohd
ORCID logo ,
Azharuddin Sajid Syed Khaja
* ORCID logo ,
Ashfaq Hossain
,
Fahaad Alenazi
,
Kamaleldin B. Said
ORCID logo ,
Soha Abdallah Moursi
,
Homoud Abdulmohsin Almalaq
,
Hamza Sharif Mohamed
,
Ehab Rakha
Version 1 : Received: 3 June 2022 / Approved: 9 June 2022 / Online: 9 June 2022 (10:58:13 CEST)

How to cite: Mohd, S.; Syed Khaja, A.S.; Hossain, A.; Alenazi, F.; Said, K.B.; Moursi, S.A.; Almalaq, H.A.; Mohamed, H.S.; Rakha, E. Molecular Characterization and Antibiogram of Acinetobacter Baumannii Clinical Isolates Recovered From the Patients With Ventilator-Associated Pneumonia. Preprints 2022, 2022060141. https://doi.org/10.20944/preprints202206.0141.v1 Mohd, S.; Syed Khaja, A.S.; Hossain, A.; Alenazi, F.; Said, K.B.; Moursi, S.A.; Almalaq, H.A.; Mohamed, H.S.; Rakha, E. Molecular Characterization and Antibiogram of Acinetobacter Baumannii Clinical Isolates Recovered From the Patients With Ventilator-Associated Pneumonia. Preprints 2022, 2022060141. https://doi.org/10.20944/preprints202206.0141.v1

Abstract

A 2-year prospective study carried out on ventilator-associated pneumonia (VAP) patients in the intensive care unit at King Khalid hospital, Hail, Kingdom of Saudi Arabia (KSA), revealed a high prevalence of extremely drug-resistant (XDR) Acinetobacter baumannii. About a 9% increase in the incidence rate of A. baumannii has occurred in the VAP patients between 2019 and 2020 (21.4% to 30.7%). In 2019 the isolates were positive for IMP-1 and VIM-2 (31.1% and 25.7%, respectively) as detected by PCR. In comparison, a higher proportion of isolates produced NDM-1 in 2020. Here, we observed a high resistant proportion of ICU isolates towards the most common antibiotics in use. Colistin sensitivity dropped to 91.4% in the year 2020 as compared to 2019 (100%). Thus, the finding of this study has a highly significant clinical implementation in the clinical management strategies for VAP patients. Furthermore, strict implementation of antibiotic stewardship policies, regular surveillance programs for antimicrobial resistance monitoring, and screening for genes encoding drug resistance phenotypes have become imperative.

Keywords

Acinetobacter baumannii; XDR; IMP-1; VIM-2; NDM-1; VAP; ICU; Hospital-acquired infections

Subject

Biology and Life Sciences, Immunology and Microbiology

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.